All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

The DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) Trial; [Studie DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure)]

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F23%3A00079491" target="_blank" >RIV/00159816:_____/23:00079491 - isvavai.cz</a>

  • Result on the web

    <a href="https://www.iakardiologie.cz/artkey/kar-202303-0010_studie_deliver_dapagliflozin_evaluation_to_improve_the_lives_of_patients_with_preserved_ejection_fraction_hear.php" target="_blank" >https://www.iakardiologie.cz/artkey/kar-202303-0010_studie_deliver_dapagliflozin_evaluation_to_improve_the_lives_of_patients_with_preserved_ejection_fraction_hear.php</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.36290/kar.2023.009" target="_blank" >10.36290/kar.2023.009</a>

Alternative languages

  • Result language

    čeština

  • Original language name

    The DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) Trial

  • Original language description

    The results of the DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) trial were presented at the 2022 European Cardiology Congress. The trial tested the effect of dapagliflozin in patients with heart failure and preserved ejection fraction. A total of 6263 patients were randomised to placebo or dapagliflozin. Dapagliflozin significantly decreased worsening of heart failure or cardiovascular death rates. The latest data show that the mechanism of action of gliflozins is much broader than expected, especially the metabolic effect. This has been confirmed by the EMPEROR Preserved and DELIVER trials. Professor Braunwald called SGLT2 inhibitors the statins of the 21st century.

  • Czech name

    The DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) Trial

  • Czech description

    The results of the DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) trial were presented at the 2022 European Cardiology Congress. The trial tested the effect of dapagliflozin in patients with heart failure and preserved ejection fraction. A total of 6263 patients were randomised to placebo or dapagliflozin. Dapagliflozin significantly decreased worsening of heart failure or cardiovascular death rates. The latest data show that the mechanism of action of gliflozins is much broader than expected, especially the metabolic effect. This has been confirmed by the EMPEROR Preserved and DELIVER trials. Professor Braunwald called SGLT2 inhibitors the statins of the 21st century.

Classification

  • Type

    J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database

  • CEP classification

  • OECD FORD branch

    30200 - Clinical medicine

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2023

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Intervenční a akutní kardiologie

  • ISSN

    1213-807X

  • e-ISSN

  • Volume of the periodical

    22

  • Issue of the periodical within the volume

    3

  • Country of publishing house

    CZ - CZECH REPUBLIC

  • Number of pages

    4

  • Pages from-to

    151-154

  • UT code for WoS article

  • EID of the result in the Scopus database

    2-s2.0-85179034721